Predictors of endothelial dysfunction in patients with rheumatoid arthritis

Angiology

Volumn 65, Issue 9, 2014, Pages 778-782

  Sarli, Bahadir ^a   Baktir, Ahmet Oguz ^a   Cebicci, Mehtap ^a   Dogan, Yasemin ^a   Demirbas, Melih ^a   Kurtul, Serkan ^a   Saglam, Hayrettin ^a   Akpek, Mahmut ^a   Sahin, Omer ^a   Arinc, Huseyin ^a  

^a KAYSERI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

atherosclerosis; endothelial dysfunction; flow mediated vasodilatation; inflammation; rheumatoid arthritis

Indexed keywords

AUTACOID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; LIPID;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD; BRACHIAL ARTERY; CASE CONTROL STUDY; DOPPLER FLOWMETRY; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FLOW-MEDIATED VASODILATATION; HUMAN; INFLAMMATION; MALE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PREDICTIVE VALUE; RHEUMATOID ARTHRITIS; RISK; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TIME; VASCULAR ENDOTHELIUM; VASODILATATION;

ATHEROSCLEROSIS; ENDOTHELIAL DYSFUNCTION; FLOW-MEDIATED VASODILATATION; INFLAMMATION; RHEUMATOID ARTHRITIS;

ADULT; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; BRACHIAL ARTERY; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LIPIDS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; ULTRASONOGRAPHY, DOPPLER; VASODILATION;

EID: 84906095092     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319713504485     Document Type: Article

References (41)

1. Chatterjee Adhikari M, Guin A, Chakraborty S, Sinhamahapatra P, Ghosh A. Subclinical atherosclerosis and endothelial dysfunction in patients with early rheumatoid arthritis as evidenced by measurement of carotid intima-media thickness and flow-mediated vasodilatation: an observational study. Semin Arthritis Rheum. 2012;41(5):669-675.
2. Goodson N, Marks J, Lunt M, Symmons D. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis. 2005;64(11):1595-1601.
3. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107(9):1303-1307.
4. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum. 2005;35(1):8-17.
5. Agewall S. Some aspects of preventing coronary heart disease. Angiology. 2012;63(1):17-23.
6. Guin A, Chatterjee Adhikari M, Chakraborty S, Sinhamahapatra P, Ghosh A. Effects of disease modifying anti-rheumatic drugs on subclinical atherosclerosis and endothelial dysfunction which has been detected in early rheumatoid arthritis: 1-year follow-up study. Semin Arthritis Rheum. 2013;43(1):48-54.
7. González-Juanatey C, Llorca J, González-Gay MA. Correlation between endothelial function and carotid atherosclerosis in rheumatoid arthritis patients with long-standing disease. Arthritis Res Ther. 2011;13(3):R101.
8. Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101(16):1899-1906.
9. Takase B, Uehata A, Akima T, et al. Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. Am J Cardiol. 1998;82(12):1535-1539.
10. Arinc H, Sarli B, Baktir AO, et al. Serum gamma glutamyl transferase and alanine transaminase concentrations predict endothelial dysfunction in patients with non-alcoholic steatohepatitis[published online July 8, 2013]. Ups J Med Sci. 2013.
11. Charakida M, Masi S, Lüscher TF, Kastelein JJ, Deanfield JE. Assessment of atherosclerosis: the role of flow-mediated dilatation. Eur Heart J. 2010;31(23):2854-2861.
12. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, et al. HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med. 2003;114(8):647-652.
13. Kumeda Y, Inaba M, Goto H, et al. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum. 2002;46(6):1489-1497.
14. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-324.
15. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44-48.
16. Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Martin J, Llorca J. Endothelial dysfunction, carotid intima-media thickness, and accelerated atherosclerosis in rheumatoid arthritis. Semin Arthritis Rheum. 2008;38(2):67-70.
17. John H, Kitas G. Inflammatory arthritis as a novel risk factor for cardiovascular disease. Eur J Intern Med. 2012;23(7):575-579.
18. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37(4):481-494.
19. Karpouzas GA, Malpeso J, Choi TY, Li D, Munoz S, Budoff MJ. Prevalence, extent and composition of coronary plaque in patients with rheumatoid arthritis without symptoms or prior diagnosis of coronary artery disease[published online July 25, 2013]. Ann Rheum Dis. 2013 Jul 25.
20. Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Douglas KM, Kitas GD. Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int. 2011;31(2):153-164.
21. Toms TE, Symmons DP, Kitas GD. Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors. Curr Vasc Pharmacol. 2010;8(3):301-326.
22. Bisoendial RJ, Hovingh GK, de Groot E, Kastelein JJ, Lansberg PJ, Stroes ES. Measurement of subclinical atherosclerosis: beyond risk factor assessment. Curr Opin Lipidol. 2002;13(6):595-603.
23. Inci M, Sarli B, Davarci M, et al. Relationship between endothelial dysfunction and nocturia with benign prostatic hyperplasia [published online January 17, 2013]. Scand J Urol. 2013.
24. Södergren A, Karp K, Boman K, et al. Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness. Arthritis Res Ther. 2010;12(4):R158.
25. John H, Kitas G, Toms T, Goodson N. Cardiovascular comorbidity in early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2009;23(1):71-82.
26. Erb N, Pace AV, Douglas KM, Banks MJ, Kitas GD. Risk assessment for coronary heart disease in rheumatoid arthritis and osteoarthritis. Scand J Rheumatol. 2004;33(5):293-299.
27. Gazi IF, Boumpas DT, Mikhailidis DP, Ganotakis ES. Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins. Clin Exp Rheumatol. 2007;25(1):102-111.
28. Carnethon MR, Gulati M, Greenland P. Prevalence and cardiovascular disease correlates of low cardiorespiratory fitness in adolescents and adults. JAMA. 2005;294(23):2981-2988.
29. Bisoendial RJ, Stroes ES, Tak PP. Critical determinants of cardiovascular risk in rheumatoid arthritis. Curr Pharm Des. 2011;17(1):21-26.
30. Burut DF, Karim Y, Ferns GA. The role of immune complexes in atherogenesis. Angiology. 2010;61(7):679-689.
31. Kalay N, Aytekin M, Kaya MG, et al. The relationship between inflammation and slow coronary flow: increased red cell distribution width and serum uric acid levels. Turk Kardiyol Dern Ars. 2011;39(6):463-468.
32. Mizuno Y, Jacob RF, Mason RP. Inflammation and the development of atherosclerosis. J Atheroscler Thromb. 2011;18(5):351-358.
33. Sarli B, Baktir AO, Saglam H, et al. Neutrophil-to-lymphocyte ratio is associated with severity of coronary artery ectasia. Angiology. 2014;65(2):147-151.
34. Lee S, Park Y, Zuidema MY, Hannink M, Zhang C. Effects of interventions on oxidative stress and inflammation of cardiovascular diseases. World J Cardiol. 2011;3(1):18-24.
35. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol. 2005;25(1):29-38.
36. Ramasamy R, Yan SF, Schmidt AM. RAGE: therapeutic target and biomarker of the inflammatory response - the evidence mounts. J Leukoc Biol. 2009;86(3):505-512.
37. Nurmohamed MT. Atherogenic lipid profiles and its management in patients with rheumatoid arthritis. Vasc Health Risk Manag. 2007;3(6):845-852.
38. Liao KP, Cai T, Gainer VS, et al. Lipid and lipoprotein levels and trends in rheumatoid arthritis compared to the general population[published online August 7, 2013]. Arthritis Care Res (Hoboken). 2013.
39. Toms TE, Panoulas VF, Douglas KM, et al. Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis? Angiology. 2011;62(2):167-175.
40. Raza K, Banks M, Kitas GD. Reversing myocardial microvascular disease in a patient with rheumatoid arthritis. J Rheumatol. 2005;32(4):754-756.
41. Khattri S, Zandman-Goddard G. Statins and autoimmunity. Immunol Res. 2013;56(2-3):348-357.